NeuroPace (NPCE) Competitors $10.39 +0.03 (+0.29%) Closing price 04:00 PM EasternExtended Trading$10.61 +0.22 (+2.12%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NPCE vs. BLFS, BBNX, SSII, KMTS, ESTA, MDXG, PLSE, INMD, IRMD, and EMBCShould you be buying NeuroPace stock or one of its competitors? The main competitors of NeuroPace include BioLife Solutions (BLFS), Beta Bionics (BBNX), SS Innovations International (SSII), Kestra Medical Technologies (KMTS), Establishment Labs (ESTA), MiMedx Group (MDXG), Pulse Biosciences (PLSE), InMode (INMD), iRadimed (IRMD), and Embecta (EMBC). These companies are all part of the "medical equipment" industry. NeuroPace vs. Its Competitors BioLife Solutions Beta Bionics SS Innovations International Kestra Medical Technologies Establishment Labs MiMedx Group Pulse Biosciences InMode iRadimed Embecta BioLife Solutions (NASDAQ:BLFS) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings. Do institutionals and insiders have more ownership in BLFS or NPCE? 93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by company insiders. Comparatively, 20.5% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts prefer BLFS or NPCE? BioLife Solutions currently has a consensus price target of $31.29, indicating a potential upside of 26.41%. NeuroPace has a consensus price target of $16.60, indicating a potential upside of 59.77%. Given NeuroPace's higher probable upside, analysts plainly believe NeuroPace is more favorable than BioLife Solutions.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLife Solutions 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13NeuroPace 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has more volatility and risk, BLFS or NPCE? BioLife Solutions has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Comparatively, NeuroPace has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Does the media favor BLFS or NPCE? In the previous week, BioLife Solutions had 5 more articles in the media than NeuroPace. MarketBeat recorded 5 mentions for BioLife Solutions and 0 mentions for NeuroPace. BioLife Solutions' average media sentiment score of 1.42 beat NeuroPace's score of 0.00 indicating that BioLife Solutions is being referred to more favorably in the media. Company Overall Sentiment BioLife Solutions Positive NeuroPace Neutral Which has stronger valuation and earnings, BLFS or NPCE? BioLife Solutions has higher revenue and earnings than NeuroPace. BioLife Solutions is trading at a lower price-to-earnings ratio than NeuroPace, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioLife Solutions$82.25M14.41-$20.18M-$0.12-206.25NeuroPace$79.91M4.30-$27.14M-$0.84-12.37 Is BLFS or NPCE more profitable? BioLife Solutions has a net margin of -5.39% compared to NeuroPace's net margin of -29.29%. BioLife Solutions' return on equity of 0.16% beat NeuroPace's return on equity.Company Net Margins Return on Equity Return on Assets BioLife Solutions-5.39% 0.16% 0.14% NeuroPace -29.29%-168.61%-25.48% SummaryBioLife Solutions beats NeuroPace on 13 of the 17 factors compared between the two stocks. Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NPCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NPCE vs. The Competition Export to ExcelMetricNeuroPaceMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$342.72M$6.83B$5.77B$10.52BDividend YieldN/A1.20%5.53%4.57%P/E Ratio-12.3725.7676.4326.62Price / Sales4.30199.41535.41119.74Price / CashN/A21.9037.4661.85Price / Book38.485.0513.616.45Net Income-$27.14M$178.07M$3.29B$271.57M7 Day Performance6.02%1.95%1.67%2.83%1 Month Performance15.57%6.81%4.05%7.27%1 Year Performance43.91%20.83%80.70%26.07% NeuroPace Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NPCENeuroPace2.6805 of 5 stars$10.39+0.3%$16.60+59.8%+38.9%$342.72M$79.91M-12.37170BLFSBioLife Solutions2.9855 of 5 stars$25.80+1.1%$31.29+21.3%-1.9%$1.22B$82.25M-214.98440BBNXBeta Bionics1.11 of 5 stars$25.31-4.2%$22.56-10.9%N/A$1.15B$65.12M0.00294Analyst ForecastSSIISS Innovations InternationalN/A$5.40-6.9%N/AN/A$1.12B$20.65M0.004KMTSKestra Medical Technologies0.6227 of 5 stars$22.68+3.9%$27.33+20.5%N/A$1.12B$59.81M0.00300Positive NewsAnalyst UpgradeHigh Trading VolumeESTAEstablishment Labs2.1709 of 5 stars$36.84-1.7%$56.50+53.4%-2.0%$1.09B$166.02M-12.081,018Positive NewsAnalyst UpgradeMDXGMiMedx Group3.4151 of 5 stars$6.97+0.4%$12.00+72.2%+17.3%$1.03B$348.88M33.19870Positive NewsPLSEPulse Biosciences4.1764 of 5 stars$15.74+8.4%$22.00+39.8%-1.7%$977.14M$700K-14.99140Positive NewsInsider TradeGap UpHigh Trading VolumeINMDInMode2.6214 of 5 stars$14.86+0.2%$18.04+21.4%-13.8%$937.39M$394.82M6.02480Positive NewsIRMDiRadimed4.7813 of 5 stars$71.61+0.5%$72.00+0.5%+47.4%$906.20M$73.24M44.20110Positive NewsEMBCEmbecta4.4463 of 5 stars$15.08+0.5%$19.00+26.0%-6.5%$877.86M$1.12B10.552,100Positive News Related Companies and Tools Related Companies BioLife Solutions Alternatives Beta Bionics Alternatives SS Innovations International Alternatives Kestra Medical Technologies Alternatives Establishment Labs Alternatives MiMedx Group Alternatives Pulse Biosciences Alternatives InMode Alternatives iRadimed Alternatives Embecta Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NPCE) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NPCE Stock Alerts